| Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis L Richeldi, RM Du Bois, G Raghu, A Azuma, KK Brown, U Costabel, ... New England Journal of Medicine 370 (22), 2071-2082, 2014 | 4749 | 2014 |
| Nintedanib in progressive fibrosing interstitial lung diseases KR Flaherty, AU Wells, V Cottin, A Devaraj, SLF Walsh, Y Inoue, ... New England Journal of Medicine 381 (18), 1718-1727, 2019 | 2055 | 2019 |
| Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report HR Collard, CJ Ryerson, TJ Corte, G Jenkins, Y Kondoh, DJ Lederer, ... American journal of respiratory and critical care medicine 194 (3), 265-275, 2016 | 1375 | 2016 |
| The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? A Moeller, K Ask, D Warburton, J Gauldie, M Kolb The international journal of biochemistry & cell biology 40 (3), 362-382, 2008 | 1128 | 2008 |
| Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis L Wollin, E Wex, A Pautsch, G Schnapp, KE Hostettler, S Stowasser, ... European Respiratory Journal 45 (5), 1434-1445, 2015 | 1009 | 2015 |
| Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis M Kolb, PJ Margetts, DC Anthony, F Pitossi, J Gauldie The Journal of clinical investigation 107 (12), 1529-1536, 2001 | 972 | 2001 |
| Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals DJ Lederer, SC Bell, RD Branson, JD Chalmers, R Marshall, DM Maslove, ... Annals of the American Thoracic Society 16 (1), 22-28, 2019 | 693 | 2019 |
| Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis A Moeller, SE Gilpin, K Ask, G Cox, D Cook, J Gauldie, PJ Margetts, ... American journal of respiratory and critical care medicine 179 (7), 588-594, 2009 | 631 | 2009 |
| Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised … AU Wells, KR Flaherty, KK Brown, Y Inoue, A Devaraj, L Richeldi, T Moua, ... The lancet Respiratory medicine 8 (5), 453-460, 2020 | 504 | 2020 |
| Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis P Bonniaud, M Kolb, T Galt, J Robertson, C Robbins, M Stampfli, C Lavery, ... The Journal of Immunology 173 (3), 2099-2108, 2004 | 488 | 2004 |
| An official American Thoracic Society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis RG Jenkins, BB Moore, RC Chambers, O Eickelberg, M Königshoff, ... American journal of respiratory cell and molecular biology 56 (5), 667-679, 2017 | 351 | 2017 |
| Proteoglycans decorin and biglycan differentially modulate TGF-β-mediated fibrotic responses in the lung M Kolb, PJ Margetts, PJ Sime, J Gauldie American Journal of Physiology-Lung Cellular and Molecular Physiology 280 (6 …, 2001 | 346 | 2001 |
| What's in a name? That which we call IPF, by any other name would act the same AU Wells, KK Brown, KR Flaherty, M Kolb, VJ Thannickal, KM Antoniou, ... European Respiratory Journal 51 (5), 2018 | 341 | 2018 |
| TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis P Bonniaud, PJ Margetts, K Ask, K Flanders, J Gauldie, M Kolb The Journal of Immunology 175 (8), 5390-5395, 2005 | 334 | 2005 |
| Progressive transforming growth factor β1–induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor P Bonniaud, PJ Margetts, M Kolb, JA Schroeder, AM Kapoun, D Damm, ... American journal of respiratory and critical care medicine 171 (8), 889-898, 2005 | 327 | 2005 |
| Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis M Kreuter, S Ehlers-Tenenbaum, K Palmowski, J Bruhwyler, U Oltmanns, ... PloS one 11 (3), e0151425, 2016 | 316 | 2016 |
| Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function PJ Margetts, M Kolb, T Galt, CM Hoff, TR Shockley, J Gauldie Journal of the American Society of Nephrology 12 (10), 2029-2039, 2001 | 298 | 2001 |
| Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin M Kolb, PJ Margetts, T Galt, PJ Sime, Z Xing, M Schmidt, J Gauldie American journal of respiratory and critical care medicine 163 (3), 770-777, 2001 | 283 | 2001 |
| Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases L Wollin, JHW Distler, EF Redente, DWH Riches, S Stowasser, ... European Respiratory Journal 54 (3), 2019 | 276 | 2019 |
| Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume M Kolb, L Richeldi, J Behr, TM Maher, W Tang, S Stowasser, C Hallmann, ... Thorax 72 (4), 340-346, 2017 | 275 | 2017 |
Jack GauldieProfessor of Pathology and Molecular Medicine, McMaster UniversityVerified email at mcmaster.ca